Takeda Pharmaceutical Limited (TAK) Return on Equity ROE from the first quarter 2026 to first quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to 0 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Takeda Pharmaceutical Company Limited  (NYSE: TAK)

Takeda Pharmaceutical Limited's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Takeda Pharmaceutical Limited in the first quarter 2026?
Takeda Pharmaceutical Company Limited achieved a return on average equity (ROE) of 4.89 % in its first quarter 2026, this is above TAK's average return on equity of 3.57%.
Takeda Pharmaceutical Company Limiteds equity during the 12 months ending in the first quarter 2026 are valued at $46 billion

ROE has advanced compared to 3.36% in the fourth quarter 2025, due to net income growth.

Within the Major Pharmaceutical Preparations industry 50 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2025 from to 2248.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
I. Quarter		 (Mar 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter
Y / Y Equity Change 0.89 % -11.21 % 13.02 % -11.21 % -
Y / Y Net Income Change - -30.16 % - 40.65 % -
Net Income (TTM) in Millions 2,260 1,549 1,847 1,847 1,598
Return On Equity (TTM) 4.89 % 3.36 % 3.89 % 4.01 % 3.37 %
TAK's Total Ranking # 2248 # # # #
Equity (TTM) in Millions 46,682 44,181 49,759 44,181 46,271
Seq. Equity Change 5.66 % -11.21 % 12.62 % -4.52 % -7.01 %
Seq. Net Income Change 3.17 % - - - -

Back to TAK Management Effectiveness >> TAK's 5 Years Annual ROE >> Compare TAK ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 51
Sector # 168
Overall # 2248

Return On Equity Statistics
High Average Low
7.58 %
3.57 %
0.93 %
(Mar 31 2021)   (Mar 31 2020)





TAK Annual Return On Equity (Mar 31 2025)
2025		 (Mar 31 2024)
2024		 (Mar 31 2023)
2023		 (Mar 31 2022)
2022		 (Mar 31 2021)
2021
Total Equity in Millions 46,271 48,102 47,869 46,801 46,806
Y / Y Equity Change -3.81 % 0.49 % 2.28 % -0.01 % 6.46 %
Net Income in Millions 710 999 2,345 2,050 3,549
Y / Y Net Income Change -28.92 % -57.41 % 14.41 % -42.23 % 770.94 %
Return On Equity 1.53 % 2.08 % 4.9 % 4.38 % 7.58 %

Back to TAK Management Effectiveness >> TAK's 5 Years Annual ROE >> Compare TAK ROE to its Competitors




Annual Roe Comment
In 2025 ROE decreased compared to the previous year to 1.53 %, due to deterioration of net income.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
TAK's' Return on Equity at Yahoo Finance
TAK's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for TAK's Competitors
Subscribers only: Roe for Takeda Pharmaceutical Limited's Suppliers
Subscribers only: Return On Equity for TAK's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
National Healthcare Corp  13.11 %
Kewaunee Scientific Corporation  12.61 %
Royalty Pharma Plc  12.37 %
Protagonist Therapeutics inc   11.80 %
Entrada Therapeutics Inc   11.77 %
Haemonetics Corporation  11.66 %
Globus Medical Inc   11.59 %
Labcorp Holdings Inc   11.58 %
Tactile Systems Technology Inc   11.49 %
Nature s Sunshine Products inc   11.26 %
Penumbra Inc  11.09 %
Henry Schein Inc   10.88 %
Cadre Holdings inc   10.76 %
Medtronic Plc  10.64 %
Viemed Healthcare Inc   10.53 %
U S Physical Therapy Inc  10.50 %
The Pennant Group Inc   10.18 %
Amphastar Pharmaceuticals Inc   10.11 %
Align Technology inc   10.09 %
Ardent Health Inc   9.92 %
Edwards Lifesciences Corporation  9.65 %
Addus Homecare Corp  9.57 %
IMPACT BIOMEDICAL INC.  9.56 %
Teva Pharmaceutical Industries Limited  9.11 %
Merit Medical Systems Inc  9.07 %
Bio techne Corp  9.01 %
Utah Medical Products Inc  8.74 %
Vaso Corporation  8.65 %
Veracyte Inc   8.64 %
Corcept Therapeutics Inc  8.27 %

Date modified: 2026-10-15T05:23:38+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.